UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 2725, 2026

INCYTE CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	001-12400	94-3136539
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)


1801 Augustine Cut-Off Wilmington, DE			19803
(Address of principal executive offices)			(Zip Code)

(302) 498-6700

(Registrant’s telephone number,

including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, $.001 par value per share	INCY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 85.0102 ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~February~~March 2725, 2026, Incyte Corporation (the U“Company”) announced title changes for certain current members of its executive leadership team, effective immediately.S Pablo J. ~~Food~~Cagnoni’s title was changed to President, Incyte and ~~Drug~~Global ~~Administration~~Head ~~(“FDA”)~~of ~~issued~~Research aand ~~Complete~~Development; ~~Response~~Steven ~~Letter~~H. ~~(“CRL”)~~Stein’s ~~for~~title ~~the~~was ~~supplemental~~changed ~~Biologics~~to ~~License~~Executive ~~Application~~Vice ~~(“sBLA”)~~President, ~~for~~Chief ~~Zynyz®~~Medical ~~(retifanlimab-dlwr)~~Officer ~~injection~~and ~~(375mg)~~Head ~~for~~of anLate-stage ~~additional~~Development; ~~indication~~and ~~for~~Mohamed ~~the~~Issa’s ~~treatment~~title ofwas ~~adult~~changed ~~patients~~to ~~with~~Executive ~~metastatic~~Vice ~~non-small~~President ~~cell~~and ~~lung~~Head ~~cancer~~of ~~(“NSCLC”)~~U.S. inCommercial. ~~combination~~Dr. ~~with~~Cagnoni ~~platinum-based~~replaces ~~chemotherapy~~William J. ~~The~~Meury ~~sBLA~~as ~~was~~President, ~~supported~~Incyte. byMr. ~~positive~~Meury ~~efficacy~~remains Chief Executive Officer and ~~safety~~a ~~data~~member ~~from~~of the ~~Phase~~Company’s 3Board ~~POD1UM-304~~of ~~trial~~Directors. ~~announced~~Mr. inMeury, ~~December~~Dr. ~~2024~~Cagnoni, Dr. Stein and Dr. Issa are collectively referred to herein as the “Impacted Executives”.

~~The~~There ~~CRL~~were ~~cited~~no ~~inspection~~changes ~~findings~~to ~~(not~~the ~~specific~~compensation toarrangements ~~Zynyz)~~between atthe ~~Catalent~~Company ~~Indiana,~~and ~~LLC~~any ~~(“Catalent~~Impacted ~~Indiana”),~~Executive ~~part~~in ofconnection ~~Novo~~with ~~Nordisk,~~these ~~the~~title ~~third-party~~changes. ~~fill-finish~~Further ~~facility~~biographical ~~referenced~~information inand ~~the~~a ~~sBLA.~~description ~~The~~of ~~CRL~~the ~~cited~~business ~~the~~experience ~~regulatory~~of ~~compliance~~each of ~~Catalent~~the ~~Indiana~~Impacted asExecutives is contained in the ~~sole~~Company’s ~~approvability~~Annual ~~issue,~~Report ~~and~~on ~~did~~Form ~~not~~10-K ~~cite~~for ~~other~~the ~~approvability~~fiscal ~~concerns~~year ended December 31, ~~including~~2025, ~~Zynyz’s~~filed ~~efficacy~~with the Securities and ~~safety~~Exchange ~~data~~Commission inon ~~NSCLC~~February or10, ~~the~~2026, ~~third-party~~which ~~drug~~are ~~substance~~incorporated ~~manufacturer~~herein by reference.

~~Incyte~~A ~~Corporation~~copy isof ~~working closely with~~ the ~~FDA~~Company’s ~~and~~press ~~Catalent~~release ~~Indiana~~announcing tothe ~~address~~title ~~the~~changes ~~CRL~~is ~~and~~attached ~~support~~as aExhibit ~~potential~~99.1 ~~sBLA~~to ~~resubmission~~this ofCurrent ~~Zynyz~~Report inon ~~NSCLC~~Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibits			Description
99.1			Press release issued by Incyte Corporation dated March 25, 2026.
104			Cover Page Interactive Data File (embedded within the Inline XBLR document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 6, 2026
Date: March 26, 2026
	INCYTE CORPORATION
	By:	/s/ Richard Hoffman
		Richard Hoffman
		Executive Vice President and General Counsel

Filing Compare · INCYTE CORP